On May 18, 2017 TG Therapeutics, Inc. (NASDAQ:TGTX), reported that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 22nd European Hematology Association (EHA) (Free EHA Whitepaper) annual congress, to be held June 22 – 25, 2017 in Madrid, Spain (Press release, TG Therapeutics, MAY 18, 2017, View Source [SID1234519240]). Schedule your 30 min Free 1stOncology Demo! Details of the data presentations are outlined below.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation:
• Title: Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL
Abstract Number: S772
Presentation Date & Time: Sunday, June 25, 2017 8:45 – 9:00 CEST
Session Title: Targeted therapies in relapsed chronic lymphocytic leukemia
Location: Hall A
Presenter: Loretta J. Nastoupil, MD, MD Anderson Cancer Center
Poster Presentation:
• Title: Combination of TGR-1202, Ublituximab, and bendamustine is safe and highly active in patients with advanced DLBCL and follicular lymphoma
Abstract Number: P563
Presentation Date & Time: Saturday, June 24, 2017 17:30 – 19:00 CEST
Session Title: Aggressive Non-Hodgkin Lymphoma- Relapsed/Refractory
Location: Poster Area Hall 7
Presenter: Matthew Lunning, DO, University of Nebraska Medical Center
The EHA (Free EHA Whitepaper) abstracts were made available today May 18, 2017 through the EHA (Free EHA Whitepaper) meeting website at www.ehaweb.org. Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com.